UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42938 Evommune, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 85-0742575 (State or other jurisdiction ...

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized to deliver on key milestones following completion of initial public offering (IPO), raising $172.5 million in gross proceeds, including the full exercise of the underwriters' option to purchase additional shares Palo Alto, Calif., December 11, 2025 – Evo ...

Company Overview - Evommune is developing next-generation therapies for chronic inflammation, which contributes to 3 out of 5 deaths worldwide[8] - The annual direct cost of chronic inflammation is at least $90 billion[9] - Evommune completed a $173 million IPO in November 2025 and has approximately $235 million in cash and investments as of September 30, 2025[115, 116] Clinical Programs - Evommune has two Phase 2 programs: EVO756 (oral MRGPRX2 antagonist) and EVO301 (long-acting IL-18 fusion protein)[15, 117] - EVO756 is being developed for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD)[20, 117] - EVO301 is being developed for atopic dermatitis and ulcerative colitis[20, 117] - Three Phase 2 data readouts are expected in 2026: EVO756 in CSU (H1 2026), EVO756 in AD (H2 2026), and EVO301 in AD (H1 2026)[20, 117] EVO756 Clinical Data - In a Phase 2 trial in chronic inducible urticaria (CIndU), both 300 mg QD and 50 mg BID doses of EVO756 demonstrated robust clinical activity, with 30% of patients achieving a complete response after just 4 weeks[47, 49] - In the CIndU trial, at week 4, patients on 300 mg QD (N=10) saw a 14 point reduction and 50 mg BID patients (N=17) saw a 15 point reduction in Mean FricTest Score (0-4)[52] EVO756 Phase 2b Trials - A Phase 2b dose-ranging trial in CSU (N = 160) is underway, with topline data expected in H1 2026[72] - A Phase 2b dose-ranging trial in AD (N = 120) is underway, with topline data expected in H2 2026[80]

Core Viewpoint - Several financial institutions have initiated coverage on various companies with positive ratings, indicating strong potential for growth and investment opportunities in their respective markets [1] Group 1: Company Initiations - UBS initiated coverage of Carvana (CVNA) with a Buy rating and a price target of $450, highlighting its "differentiated, best-in-class" online platform and customer experience, which positions it well in the large used vehicle market [1] - Benchmark initiated coverage of Cal-Maine Foods (CALM) with a Buy rating and a price target of $100, suggesting that the company's valuation is undervalued due to its legacy as a commodity producer, despite significant changes in the egg category and a shift towards more valuable specialty production [1] - Goldman Sachs initiated coverage of Beta Technologies (BETA) with a Buy rating and a price target of $47, viewing it as the best positioned among electric vertical take-off and landing companies, with multiple other firms also starting coverage with Buy-equivalent ratings [1] - JPMorgan initiated coverage of BillionToOne (BLLN) with an Overweight rating and a price target of $150, noting the company's potential to build its commercial infrastructure to meet growing demand in prenatal and oncology sectors, with several other firms also starting coverage with Buy-equivalent ratings [1] - Morgan Stanley initiated coverage of Evommune (EVMN) with an Overweight rating and a price target of $36, seeing favorable risk/reward for the shares despite early-stage data for its products, with other firms also starting coverage with Buy-equivalent ratings [1]

Core Insights - Three companies, Evommune, BillionToOne, and Grupo Aeroméxico, went public on November 6, raising a total of $646 million, averaging approximately $215 million per company [1] Group 1: Evommune (EVMN) - Evommune opened at $17.25, a 7.25% increase from the offering price, and closed at $20.23, marking a 26.44% rise with a total market capitalization of $608 million [2][5] - The company issued 9.38 million shares at an offering price of $16, raising $150 million [5] - Evommune focuses on innovative therapies for immune-mediated inflammatory mechanisms, projecting $3 million in revenue and a net loss of $28.12 million for the first half of 2025 [5] Group 2: BillionToOne (BLLN) - BillionToOne opened at $100, a 66.67% increase from the offering price, and closed at $108.94, reflecting an 81.57% gain with a total market capitalization of $4.795 billion [6][9] - The company issued 4.55 million shares at an offering price of $60, raising $273 million [9] - BillionToOne specializes in molecular diagnostics, developing prenatal and oncology diagnostic products through its single-molecule next-generation sequencing (smNGS) platform, with projected revenue of $126 million and a net loss of $4.23 million for the first half of 2025 [9] Group 3: Grupo Aeroméxico (AERO) - Grupo Aeroméxico opened at $19.16, a slight increase of 0.84%, and closed at $20.35, resulting in a 7.11% rise with a total market capitalization of $2.969 billion [9][11] - The company issued 11.73 million shares at an offering price of $19, raising $223 million [11] - Grupo Aeroméxico provides domestic and international flight services, covering 22 countries and 52 international cities, with projected revenue of $2.498 billion and a net profit of $89.97 million for the first half of 2025 [11]

Evommune(EVMN.US)登陆美股市场，截至发稿，该股涨超15%，报18.38美元，IPO价格为16美元。 Evommune是一家临床阶段的生物医药公司，其使命是通过创新疗法，治疗"免疫介导的慢性炎症性疾 病"。这类疾病包括慢性荨麻疹、特应性皮炎、其他与肥大细胞/炎症相关的病症。 ...

智通财经APP获悉，Evommune(EVMN.US)登陆美股市场，截至发稿，该股涨超15%，报18.38美元， IPO价格为16美元。Evommune 是一家临床阶段的生物医药公司，其使命是通过创新疗法，治疗 "免疫 介导的慢性炎症性疾病"。这类疾病包括慢性荨麻疹、特应性皮炎、其他与肥大细胞/炎症相关的病症。 ...

Core Points - Evommune, Inc. has priced its initial public offering (IPO) at $16.00 per share, offering 9,375,000 shares, with expected gross proceeds of $150 million [1][2] - The shares are set to begin trading on the New York Stock Exchange under the symbol "EVMN" on November 6, 2025, with the offering expected to close on November 7, 2025 [2] - The company is focused on developing innovative therapies targeting chronic inflammatory diseases, aiming to improve patients' daily lives and address the limitations of existing therapies [5] Company Overview - Evommune, Inc. is a clinical-stage biotechnology company dedicated to creating therapies that address key drivers of chronic inflammatory diseases [5] - The company's mission includes preventing long-term effects of uncontrolled inflammation through a portfolio of differentiated product candidates [5] Offering Details - The IPO includes a 30-day option for underwriters to purchase an additional 1,406,250 shares at the initial offering price [1] - Joint book-running managers for the offering include Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor [2]

Core Insights - Eight new stocks were listed last week, including one direct listing company, raising significant capital across various sectors [1][2][3]. Group 1: Recent IPOs - MapLight Therapeutics (MPLT) raised $251 million by issuing 14.75 million shares at $17 each [1]. - Navan (NAVN) raised $923 million by issuing 36.92 million shares at $25 each [1]. - Boyd Group Services (BGSI) raised $780 million by issuing 5.5 million shares at $141 each [2]. - Nomadar (NOMA) entered Nasdaq through a direct listing [3]. Group 2: Upcoming IPOs - BETA Technologies, Inc. plans to list on NYSE with a target date of November 4, 2025, aiming to raise approximately $825 million by issuing 25 million shares at $27 to $33 each. The company reported revenue of $15.57 million in the first half of 2025, up from $7.59 million in the same period last year, with a net loss of $159 million [4][6]. - Exzeo Group, Inc. plans to list on NYSE on November 5, 2025, aiming to raise about $176 million by issuing 8 million shares at $20 to $22 each. The company reported revenue of $109 million in the first half of 2025, up from $60.31 million year-over-year, with a net profit of $39.61 million [6][8]. - Evommune, Inc. plans to list on NYSE on November 6, 2025, aiming to raise approximately $159 million by issuing 9.38 million shares at $15 to $17 each. The company reported revenue of $3 million in the first half of 2025, down from $7 million year-over-year, with a net loss of $28.12 million [10]. - Grupo Aeroméxico, S.A.B. de C.V. plans to list on NYSE on November 6, 2025, aiming to raise about $235 million by issuing 11.73 million shares at $18 to $20 each. The company reported revenue of $2.498 billion in the first half of 2025, down from $2.695 billion year-over-year, with a net profit of $89.97 million [12]. - BillionToOne, Inc. plans to list on NASDAQ on November 6, 2025, aiming to raise approximately $212 million by issuing 3.85 million shares at $49 to $55 each. The company reported revenue of $126 million in the first half of 2025, up from $69.09 million year-over-year, with a net loss of $4.23 million [14]. - Off The Hook YS Inc. plans to list on NYSE MKT on November 7, 2025, aiming to raise about $30 million by issuing 5 million shares at $4 to $6 each. The company reported revenue of $58.59 million in the first half of 2025, up from $51.85 million year-over-year, with a net profit of $840,000 [16].

Core Points - Evommune, Inc. has filed a registration statement for an initial public offering (IPO) of its common stock, offering 9,375,000 shares at an expected price between $15.00 and $17.00 per share [1] - The company plans to grant underwriters a 30-day option to purchase an additional 1,406,250 shares in connection with the IPO [1] - Evommune's common stock is expected to be listed on the New York Stock Exchange under the symbol "EVMN" [1] - The registration statement is anticipated to become effective on November 5, 2025, allowing the company to price the offering shortly thereafter [1] - Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are acting as joint book-running managers for the proposed offering [2] Company Overview - Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies targeting chronic inflammatory diseases [5] - The company's mission is to enhance patients' daily lives and mitigate long-term effects of uncontrolled inflammation caused by existing therapy limitations [5] - Evommune is advancing a portfolio of differentiated product candidates aimed at addressing key drivers of chronic inflammation [5]